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Recent studies show that hyperactivated mTOR, the
‘target of rapamycin’ that senses nutrient availability
in eukaryotic cells, inhibits signaling by insulin
receptor substrates. This crosstalk reveals how
hyperactivated mTOR may suppress metastasis
locally, while causing systemic insulin resistance
that can progress to diabetes.
This story begins with a rare genetic disease known as
tuberous sclerosis, which causes benign tumors in
various organs and results from mutations in one or the
other of two identified genes TSC1 and TSC2.
Tuberous sclerosis afflicts some people severely,
causing developmental delay, mental retardation and
autism, while others are so mildly affected that the
condition goes undiagnosed. Regardless of the clinical
presentation, the tumors in tuberous sclerosis patients,
also known as hamartomas, are rarely malignant.
The TSC1 and TSC2 proteins form a heterodimer
which acts as a GTPase activating protein (GAP) that
links upstream growth factor signaling cascades to
the ‘target of rapamycin’, mTOR, a serine/threonine
kinase that regulates protein synthesis through down-
stream effectors such as ribosomal S6 kinase (S6K)
and the translation factor inhibitor 4EBP1. This
pathway is critical for proper cell growth and regula-
tion of organ size [1]. Growth factor signals, such as
insulin, insulin-like growth factor (IGF), platelet-derived
growth factor and others, activate mTOR when nutri-
ents are available and intracellular energy levels are
high; mTOR is inactivated during cellular starvation [2].
The mutations that cause tuberous sclerosis inactivate
the GAP activity of the TSC1–TSC2 heterodimer
leading to uncontrolled hyperactivation of mTOR.
The insulin and IGF1 receptors are tyrosine kinases
which phosphorylate the insulin receptor substrate (IRS)
upon ligand binding. Phosphorylated IRS, in turn, acts
as a protein scaffold that activates the phosphatidyli-
nositol (PI) 3-kinase/Akt cascade [3]. The production of
PIP3 by PI 3-kinase recruits the serine/threonine kinases
PDK1 and Akt to the plasma membrane, where Akt is
activated by PDK1-mediated phosphorylation [4]. Akt
phosphorylates many proteins with important physio-
logical roles, including TSC2, inhibiting its GAP activity
toward the small G-protein Rheb [5]. The accumulation
of GTP-bound Rheb leads to activation of mTOR
through an as yet unknown mechanism (Figure 1).
As mentioned above, mutations in TSC1 or TSC2
that promote activation of mTOR cause benign hamar-
tomas that rarely metastasize. By contrast, activation
of mTOR by mutations that stimulate Akt causes
malignant tumors. An explanation for this difference is
revealed, at least in part, by two recent studies [6,7]
which use mouse embryo fibroblasts deficient in either
TSC1 or TSC2 to dissect the pathway components
altered in tuberous sclerosis. Both groups [6,7] found
the PI 3-kinase/Akt cascade in TSC1–/– and TSC2–/–
mouse embryo fibroblasts is insensitive to insulin or
IGF1, whereas other growth factors stimulate the
pathway normally. Insulin-stimulated Akt activation is
restored in these mutant cells upon inhibition of mTOR
or S6K activity. Shah et al. [6] report that over-expres-
sion of Rheb in HEK293 cells mimics TSC1 or TSC2
deficiency. These data indicate that hyperactivation of
mTOR/S6K signaling blocks the activation of PI 3-
kinase/Akt during insulin or IGF stimulation.
The IRS proteins are unique elements in the insulin
and IGF signaling cascade and thus likely sites of
mTOR-mediated inhibition. Earlier work showed that
many kinases, including rapamycin-sensitive enzymes,
promote serine/threonine phosphorylation of IRS1 and
IRS2 that inhibits their function and promotes their
degradation [8,9]. Shah et al. [6] found that IRS1 and
IRS2 protein levels are reduced in TSC1–/– and TSC2–/–
cells as a result of their decreased half-life and lower
transcript levels. Harrington et al. [7] found specific loss
of IRS1 at the mRNA and protein level in TSC2–/– cells. 
Regardless of these differences, both groups [6,7]
found that insulin or IGF stimulated Akt phosphoryla-
tion could be rescued by rapamycin treatment,
coincident with restored IRS protein levels. The
rapamycin-mediated rescue was blunted by reducing
IRS1 or IRS2 expression with specific siRNAs, and ren-
dered unnecessary by overexpression of IRS1. Thus,
chronic hyperactivation of mTOR by inactivation of
TSC1–TSC2 stimulates components of the protein
synthesis pathway, while inhibiting the IRS branch of
the insulin/IGF signaling cascade [6,7].
Dysregulation of IRS1 or IRS2 upstream of the PI 3-
kinase/Akt signaling pathway may be critical to the
benign nature of tumors in tuberous sclerosis. TSC2–/–
cells display no chemotaxis toward IGF1, but retain
the ability to move towards epidermal growth factor
(EGF) [7]. Moreover, TSC1–/– and TSC2–/– cells are
more sensitive to apoptotic stimuli such as serum
withdrawal or etoposides, consistent with the view
that IGF1 signaling is inactive in these mutant cells
[6,7]. Rapamycin treatment restores both cell survival
and the chemotactic response to IGF1, raising a
caution about the indiscriminant use of rapamycin in
cancer therapy [6,7].
Nagle et al. [10] recently reported that IRS2 acts to
promote lung metastases in murine primary breast
cancer caused by mammary-specific expression of
transforming middle T antigen. Thus, depletion of IRS
proteins by the hyperactivated mTOR cascade could
explain, at least in part, the infrequent malignancy of
tuberous sclerosis tumors. A second mutation that
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activates PI 3-kinase/Akt signaling, such as one that
hyperactivates the EGF receptor or inactivates PTEN,
might promote malignant tumor formation in tuberous
sclerosis patients. Regardless, strategies aimed at
inhibiting IRS protein signaling may provide a rational
way of targeting IGF-dependent malignant tumors of
mammary, colon or prostate origin.
The mechanisms directed by mTOR that inhibit IRS
protein function are difficult to resolve. Harrington et al.
[7] explored the role of IRS serine/threonine phospho-
rylation in TSC2–/– cells. IRS1 and IRS2 each contain
over 40 serine/threonine phosphorylation sites, many
of which appear to inhibit insulin signaling (White lab’s
unpublished data). One site in IRS1, serine 302, was
found to be hyperphosphorylated in TSC2–/– cells, but
returns to the wild-type state upon treatment with
rapamycin or specific siRNAs against S6K1 and S6K2
[7]. In vitro assays have shown that phosphorylation of
serine 302 interferes with the association between
IRS1 and the insulin receptor, as proposed for serine
307 phosphorylation in IRS1 [11]. Harrington et al. [7]
conclude that phosphorylation of serine 302 is a key
step to inhibiting IRS-protein functions.
The mechanisms that regulate IRS function are
likely to be more complicated, as the mTOR cascade
also has a permissive role when nutrients are avail-
able. Starvation for amino acids or glucose inhibits
insulin/IGF1-stimulated tyrosine phosphorylation of
IRS1, while diminishing serine 302 phosphorylation.
Replenishing amino acids restores serine 302 phos-
phorylation and insulin-stimulated tyrosine phospho-
rylation of IRS1; however, mutation of serine 302 to
alanine inhibits insulin-stimulated tyrosine phosphory-
lation of IRS1 even when amino acids are present [12].
Thus, mTOR might be a dual checkpoint enzyme:
under ordinary conditions, mTOR signaling promotes
the interaction between IRS and the insulin/IGF1
receptor; but when mTOR is hyperactivated, either
during chronic nutrient excess or in TSC1–/– or TSC2–/–
cells, it promotes hyperphosphorylation of IRS1 that
inhibits insulin/IGF signaling (Figure 2).
Physiological conditions that lead to constitutive
activation of the mTOR cascade, such as the hyperin-
sulinemia that accompanies chronic nutrient excess
and obesity, may exacerbate the insulin resistance that
causes metabolic disease and type 2 diabetes. Long-
term treatment of mouse embryo fibroblasts with insulin
or IGF1 promotes rapamycin-sensitive degradation of
IRS2 by an ubiquitin-mediated and proteosome-depen-
dent process. This cellular state causes inhibition of
insulin/IGF-stimulated Akt activation [9]. Perhaps spe-
cific phosphoserine sites on IRS proteins promote ubiq-
uitinylation and proteosome-mediated degradation.
Regardless of the exact mechanism by which mTOR is
hyperactivated, cellular insulin resistance appears to be
an inevitable consequence.
Can hyperactivation of the mTOR/S6K cascade
contribute to systemic insulin resistance? A recent
analysis [13] of S6K1–/– mice supports the view that
S6K1 has an important role in the inhibition of IRS1
signaling by diet or obesity. Wild-type mice fed a high
fat diet display increased S6K phosphorylation,
indicative of active kinase, and reduced Akt phospho-
rylation upon acute insulin stimulation in adipose, liver
and muscle [13]. Moreover, IRS1 from obese wild-type
mice is hyperphosphorylated on serine 307 and
serines 636/639 in adipose tissue; phosphorylation at
the latter sites inhibits IRS1 and PI 3-kinase binding
[8]. By contrast, insulin-stimulated Akt phosphoryla-
tion and IRS1 serine phosphorylation were found to be
nearly normal in S6K1–/– mice fed a high fat diet [13].
Um et al. [13] conclude that excess nutrients resulting
from an inappropriate diet or chronic obesity may
cause insulin resistance through hyperactivation of
the mTOR/S6K cascade, which disrupts IRS function
via serine phosphorylation events.
Simple organisms like yeast or cultured eukaryotic
cells rely upon mTOR as a checkpoint to integrate
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Figure 1. Growth factors and nutrient
signaling regulate the mTOR
serine/threonine kinase and its
downstream effectors S6K and 4E-BP1.
When activated by ligand binding, the
insulin receptor kinase recruits IRS mole-
cules and phosphorylates them on tyro-
sine residues that serve as docking sites
for downstream signaling molecules such
as PI 3-kinase. Activated PI 3-kinase trig-
gers a ubiquitous lipid and protein kinase
cascade; the signal propagates through
Akt to TSC1–TSC2 heterodimers and the
small G protein Rheb, leading to mTOR
activation. Nutrients such as glucose and
amino acids are required for complete
activation of mTOR and S6K. Rheb and
TSC1–TSC2 are also sensitive to nutrient
availability. Rapamycin is a bacterial
product that forms a complex with a
protein known as FKBP that binds to
mTOR and inhibits its kinase activity.
Phosphorylation of mTOR effector pro-
teins, such as the serine/threonine kinase S6K and 4E-BP1, is critical for protein synthesis and cell proliferation. Several kinases are
known to promote the phosphorylation of IRS, as shown. Rapamycin-sensitive ubiquitinylation of IRS molecules leads to their uncou-
pling from the insulin receptor and degradation. Black arrows indicate stimulatory events and red arrows indicate inhibitory events.
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cellular growth and function with available nutrients
and intracellular energy stores. As complex animals,
including worms, flies and humans, emerged, insulin
signaling evolved to provide system-wide integration,
extending to the peripheral tissues and the central
nervous system. Mice lacking Irs1 are small and
insulin resistant, while those lacking Irs2 develop type
2 diabetes mellitus as a result of peripheral insulin
resistance and pancreatic β cell failure [14]. The dis-
covery that IRS is inhibited by mTOR/S6K cascades
has revealed an elusive connection between nutrient
homeostasis and normal growth, and tumor formation
and metastasis.  In the central nervous system, this
mechanism might inhibit Irs2 signaling, promoting
hyperphagia that exacerbates nutrient excess [15]. By
contrast, exercise-induced activation of the AMP
kinase that down-regulates mTOR activity might
promote IRS–protein signaling in peripheral insulin-
sensitive tissues that prevents obesity and diabetes.
A number of important questions remain unan-
swered. Does the low incidence of malignancy in
tuberous scleroris arise from the depletion of IRS
proteins, and could this model be generally applied in
cancer treatment? Might tissue-specific inhibition of
mTOR be a treatment for metabolic diseases and type
2 diabetes, especially as IRS2 is critical at multiple
levels for nutrient homeostasis [15,16]? Might the
protection of IRS protein levels in β cells explain why
rapamycin is the best immunosuppressive drug for
islet transplant recipients? Understanding the
crosstalk between IRS and the mTOR cascade should
provide answers to these questions, while revealing
strategies to achieve a healthy balance between nutri-
ent homeostasis and dysregulated cell growth.
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Figure 2. A model in which mTOR acts as
a dual checkpoint regulating IRS
signaling.
Inactive or hyperactivated mTOR inhibits
insulin-stimulated tyrosine phosphoryla-
tion of IRS proteins. IRS-1 is primed to
interact with activated insulin or IGF1
receptors by a rapamycin-sensitive
serine phosphorylation, probably involv-
ing nutrient-activated mTOR. Primed
IRS1 is strongly tyrosine phosphorylated
during insulin stimulation, which leads to
activation of downstream effectors, such
as the PI 3-kinase/Akt cascade, that
stimulate mTOR/S6K signaling. The
second phase of mTOR regulation of
IRS1, possibly involving S6K and many
other kinases, promotes extensive phos-
phorylation of multiple serine and threo-
nine residues throughout IRS1.
Hyperphosphorylated IRS1 is uncoupled
from receptor tyrosine kinases, interacts
poorly with downstream effectors and is
targeted for degradation. This model can explain how severe starvation can inhibit insulin signaling, while excess calories and
chronic hyperinsulinemia can elevate mTOR activity sufficiently to contribute to peripheral insulin resistance. Inactivation of
TSC1–TSC2 dimers leads to hyperactivation of mTOR and complete inhibition of IRS signaling. By contrast, dysregulation of S6K
in cells or deletion of the S6K1 gene in mice reduces serine phosphorylation of IRS proteins, stabilizes the protein at levels that
promote insulin signaling [13].
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